{"organizations": [], "uuid": "b10ae4684ee5d1d65e9328a58112b13ab33d4851", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-audentes-therapeutics-q4-loss-per/brief-audentes-therapeutics-q4-loss-per-share-0-82-idUSASB0C9J9", "country": "US", "domain_rank": 408, "title": "BRIEF-Audentes Therapeutics Q4 Loss Per Share ‍$0.82", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.097, "site_type": "news", "published": "2018-03-09T05:19:00.000+02:00", "replies_count": 0, "uuid": "b10ae4684ee5d1d65e9328a58112b13ab33d4851"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-audentes-therapeutics-q4-loss-per/brief-audentes-therapeutics-q4-loss-per-share-0-82-idUSASB0C9J9", "ord_in_thread": 0, "title": "BRIEF-Audentes Therapeutics Q4 Loss Per Share ‍$0.82", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "audentes therapeutics inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Audentes Therapeutics Inc:\n* AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* AUDENTES THERAPEUTICS INC - ‍PLAN TO FILE IND MID-2018 AND INITIATE A PHASE 1/2 CLINICAL TRIAL OF AT982 IN Q4 OF 2018​\n* AUDENTES THERAPEUTICS INC QTRLY LOSS PER SHARE ‍$0.82 * AUDENTES THERAPEUTICS INC - ‍CURRENT CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS ARE PLANNED TO FUND OPERATIONS INTO SECOND HALF OF 2020​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-09T05:19:00.000+02:00", "crawled": "2018-03-09T14:18:01.000+02:00", "highlightTitle": ""}